Hims & Hers Health (HIMS) to Release Quarterly Earnings on Monday

Hims & Hers Health (HIMS) is projected to report Q3 2025 earnings of $0.09 per share and $578.99 million in revenue on November 3rd. This follows a recent quarter where the company missed analyst estimates with $0.17 EPS and $544.83 million in revenue, despite achieving 72.6% year-over-year revenue growth. Notably, the stock, which recently traded up 3.4%, has experienced substantial insider selling, with executives, including the CFO, offloading over $74 million in shares over the past three months, while institutional ownership stands at 63.52%.

Analysis

Hims & Hers Health (HIMS) is projected to report Q3 2025 earnings of $0.09 per share on revenue of $578.99 million, following a recent quarter where the company missed analyst consensus. In the last reported quarter, HIMS posted $0.17 EPS against $0.18 estimates and $544.83 million in revenue versus $550.06 million expected, despite achieving robust 72.6% year-over-year revenue growth. The company demonstrated strong profitability with a 26.26% return on equity and a 9.63% net margin.

A significant point of concern is the substantial insider selling, with executives, including the CFO, offloading over $74 million in shares over the past three months, representing a 52.92% decrease in the CFO's ownership. This insider activity contrasts with the high institutional ownership, which stands at 63.52% of the stock.

The stock, currently trading at $45.55 and up 3.4% recently, carries a high valuation with a P/E ratio of 56.94 and a P/E/G ratio of 3.05. The overall market sentiment for HIMS is moderately negative and cautious, reflecting potential investor apprehension despite the company's growth trajectory.

Key Decisions for Investors

• Investors should closely monitor the upcoming Q3 2025 earnings report for HIMS, focusing on actual EPS and revenue figures against analyst projections to assess growth sustainability.
• Evaluate the implications of the significant insider selling, particularly from key executives, as this could signal internal concerns despite the company's revenue growth and institutional interest.
• Consider the company's high valuation multiples (P/E 56.94, PEG 3.05) in the context of future growth prospects and the prevailing cautious market sentiment, potentially adjusting position sizing accordingly.